AI adoption in biotech has outpaced operational maturity.

Twelve source-linked pages on why AI use is spreading faster than governed operating capability, and a practical 90-day agenda to close the gap.

• What FDA, EMA, NIST, and the EU are signaling on evidence, oversight, and lifecycle control
• Where AI fits across discovery, clinical, regulatory, and operations work, and where agents raise the risk
• A four-level maturity model and a practical 90-day path from pilots to governed capability
• A ten-question scorecard for finding the operating constraint closest to the decision